Real World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900241247618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Preethi S Samuel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA. Hauptthemen laut MEDLINE: Pyridones, HIV Infections, Heterocyclic Compounds, 3-Ring, Cobicistat. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Background
Despite the effectiveness of the TRIO regimen in maintaining viral suppression, as seen in the ANRS 139 TRIO trial, one drawback is the high pill burden. However, with the development of newer antiretrovirals, this regimen can be simplified. The combination of both co-formulated darunavir/cobicistat and dolutegravir/rilpivirine keeps the integrity of the TRIO regimen while decreasing daily pill count from 12 to 2 tablets daily. The purpose of this case series is to demonstrate the efficacy of this regimen as there is a current lack of data.
Methods
This case series included patients with no resistance to dolutegravir, rilpivirine, or darunavir, who were switched to the modified TRIO regimen between June 1st 2018 to June 1st 2022. The primary outcome was the proportion of patients with plasma HIV-RNA levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, The Brooklyn Hospital Center, Brooklyn, NY, USA.
- Department of Pharmacy, Staten Island University Hospital, Staten Island, NY, USA.
- Department of Pharmacy, The Brooklyn Hospital Center, Brooklyn, NY, USA.
- Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University (LIU Pharmacy), Brooklyn, NY, USA.
- Program for AIDS Treatment and Health (PATH) Center, The Brooklyn Hospital Center, Brooklyn, NY, USA.
ORCID-Profile: Preethi S Samuel, Folake Olaleye
Zitieren
APA
Samuel, P. S., Olaleye, F., Longo, M., & Berkowitz, L. (2024). Real World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241247618
Vancouver
Samuel PS, Olaleye F, Longo M, Berkowitz L. Real World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900241247618
BibTeX
@article{Samuel2024,
author = {Samuel, Preethi S and Olaleye, Folake and Longo, Maria and Berkowitz, Leonard},
title = {Real World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900241247618}
}
EUVIMED